BMBF Project: Improving diagnostics and therapy of food hypersensitivity

July 1, 2021

Food hypersensitivity (FH) is common in clinical routine and presents frequently with gastrointestinal (GI) symptoms. This type of FH is difficult to diagnose since clinical symptoms are rather unspecific and efficient biomarkers do not exist. As a consequence many of the FH patients are misdiagnosed with irritable bowel syndrome (IBS). The uncertainty of the diagnosis, the trivialization and stigmatization of the disease by medical professionals and the fear of uncontrollable GI symptoms lead to a significantly reduced quality of life and creates a high socioeconomic burden. In order to overcome the diagnostic and therapeutic restrictions we build an interdisciplinary consortium that applies cutting edge technologies in combination with patient focused clinical trials. Since one of the most common culprit for clinical manifestations of the FH with GI symptoms only is wheat, the overall goal of the consortium is to improve diagnostics of the wheat-related disorders and as such to evaluate the confocal laser endomicroscopy (CLE) as a diagnostic tool for discriminating endoluminal IgE-mediated FA from other FHs (such as celiac disease and non-celiac wheat sensitivity-NCWS).

The consortium gathers experts in allergology, gastroenterology and nutritional medicine from the Universities of Lübeck, and Hohenheim and the Leibniz Research Center Borstel. This broad clinical expertise is complemented by leading scientists with background in microbiome research, artificial intelligence, biometry and statistics. Furthermore, the consortium is joined by Perfood, a start-up dedicated to provide digital solutions for personalized nutrition, Mauna Kea Technologies, the leading company in the field of endomicroscopy and The German Coeliac Society e.V. Together the consortium has full access to annually more than 1800 patients with FH, high end endoscopy, an own clinical trial unit and competitive laboratories. All together we will provide scientific-based innovative solutions for significantly improved individualized diagnostics, tailored therapeutic and prevention measures for patients suffering from FH.

Link to press release